Ascendis Pharma A/S announced its financial results for the second quarter ended June 30, 2025, reporting total revenue of €158.0 million. This represents a substantial increase from €36.0 million in the same period of 2024, primarily driven by strong product revenue contributions.
YORVIPATH revenue more than doubled sequentially to €103.0 million in Q2 2025, demonstrating robust global uptake. SKYTROFA also contributed significantly with €50.7 million in revenue for the quarter. The company reported a net loss of €38.9 million, or €0.64 per share basic, a notable reduction from a net loss of €109.4 million in Q2 2024.
Ascendis Pharma ended the quarter with €494 million in cash and cash equivalents. The company highlighted that TransCon CNP's NDA is under Priority Review with a PDUFA date of November 30, 2025, and SKYTROFA received U.S. FDA approval for adult growth hormone deficiency. These developments, along with positive interim COACH trial results, position Ascendis for continued momentum towards its Vision 2030 goals.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.